Mr. Turner has served as an independent director and audit committee chair for multiple biotech companies over the last decade. He currently serves on the board of BioClin Therapeutics. In recent years, he has served on the boards of Corcept Therapeutics, Kythera Biotherapeutics, Alexza Pharmaceuticals, Nora Therapeutics, Sophiris Bio, QLT and SGX Pharmaceuticals.
Mr. Turner has served as an independent director and audit committee chair for multiple biotech companies over the last decade. He currently serves on the board of BioClin Therapeutics. In recent years, he has served on the boards of Corcept Therapeutics, Kythera Biotherapeutics, Alexza Pharmaceuticals, Nora Therapeutics, Sophiris Bio, QLT and SGX Pharmaceuticals.
Mr. Turner previously as served as the chief financial officer of Myogen, Inc. from 1999 until it was acquired by Gilead Sciences in 2006. Previously, he served as the chief financial officer of Centaur Pharmaceuticals from 1997 to 1999 and as the chief financial officer and vice president, finance and administration at Cortech, Inc. from 1992 to 1997. Prior to Cortech, he was employed by Eli Lilly from 1979 to 1991 in a variety of finance and administration roles.
Mr. Turner holds an MBA from University of North Carolina at Chapel Hill, an M.A. in molecular, cellular and developmental biology from University of Colorado and a B.A. in chemistry with a minor in biology from Swarthmore College. Since 2009, he has served on the board of managers of Swarthmore College where at various times he has served on its executive committee, finance committee, audit committee, academic affairs committee and student affairs committee and property committee.